Endo Tools Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Endo Tools Therapeutics's estimated annual revenue is currently $7.8M per year.
- Endo Tools Therapeutics's estimated revenue per employee is $251,000
Employee Data
- Endo Tools Therapeutics has 31 Employees.
- Endo Tools Therapeutics grew their employee count by 11% last year.
Endo Tools Therapeutics's People
| Name | Title | Email/Phone |
|---|
Endo Tools Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Endo Tools Therapeutics?
Endo Tools Therapeutics (ETT) is a Belgian privately held medical device company. The company is dedicated to the development of innovative devices providing new means of therapeutic interventions for gastroenterologists.
keywords:N/A
N/A
Total Funding
31
Number of Employees
$7.8M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Endo Tools Therapeutics News
2022-04-20 - Fierce Pharma AsiaMerck's former China head returns
The agreements will make Fujifilm's endoscopy equipment available to all medical ... and develop new innovative therapeutics that serve unmet patient needs.
2022-04-19 - Advanced Drug Delivery Systems Market to record USD 91.79 ...
... Endo International Plc, NanoPass Technologies Ltd., Nektar Therapeutics, Perrigo Co. Plc, and Teva Pharmaceutical Industries Ltd.
Other Companies in Gosselies
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5M | 32 | -26% | N/A |
#2 | $10.4M | 67 | -12% | N/A |
#3 | $13.5M | 87 | 28% | N/A |
#4 | $14.9M | 96 | 37% | $83.7M |
#5 | $29.7M | 110 | 1% | N/A |